Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cassidy P Pumper"'
Autor:
Sebastian I Arriola Apelo, Amy Lin, Jacqueline A Brinkman, Emma Meyer, Mark Morrison, Jay L Tomasiewicz, Cassidy P Pumper, Emma L Baar, Nicole E Richardson, Mohammed Alotaibi, Dudley W Lamming
Publikováno v:
eLife, Vol 9 (2020)
Inhibition of mTOR (mechanistic Target Of Rapamycin) signaling by rapamycin promotes healthspan and longevity more strongly in females than males, perhaps because inhibition of hepatic mTORC2 (mTOR Complex 2) specifically reduces the lifespan of male
Externí odkaz:
https://doaj.org/article/c95333fc539a4d298a632aafbb9b83b4
Autor:
Nicole E. Richardson, Jay L. Tomasiewicz, Cassidy P. Pumper, Emma L. Baar, Mark Morrison, Sebastian I. Arriola Apelo, Emma Meyer, Dudley W. Lamming, Amy Lin, Mohammed I. Alotaibi, Jacqueline A. Brinkman
Publikováno v:
eLife
eLife, Vol 9 (2020)
eLife, Vol 9 (2020)
Inhibition of mTOR (mechanistic Target Of Rapamycin) signaling by rapamycin promotes healthspan and longevity more strongly in females than males, perhaps because inhibition of hepatic mTORC2 (mTOR Complex 2) specifically reduces the lifespan of male
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f38f88e1a0f1d8d86a766a004768f2be
https://pubmed.ncbi.nlm.nih.gov/32720643
https://pubmed.ncbi.nlm.nih.gov/32720643
Autor:
Michelle E. Kimple, Sebastian I. Arriola Apelo, Cassidy P. Pumper, Faizan A. Syed, Nicole E. Cummings, Harpreet K. Brar, Emma L. Baar, Dudley W. Lamming, Joshua C. Neuman
Publikováno v:
Aging Cell
Summary Inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway by the FDA‐approved drug rapamycin has been shown to promote lifespan and delay age‐related diseases in model organisms including mice. Unfortunately, rapamycin ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03d7d2a323fbfc698e2f43ae3a62499b
https://doi.org/10.1111/acel.12405
https://doi.org/10.1111/acel.12405
Autor:
Cassidy P. Pumper, Sebastian I. Arriola Apelo, Nicole E. Cummings, Emma L. Baar, Dudley W. Lamming
Inhibition of the mTOR (mechanistic target of rapamycin) signaling pathway by the FDA-approved drug rapamycin promotes life span in numerous model organisms and delays age-related disease in mice. However, the utilization of rapamycin as a therapy fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e938343b7c8f64181d151a05bf956b02
https://europepmc.org/articles/PMC4906329/
https://europepmc.org/articles/PMC4906329/
Publikováno v:
Innovation in Aging. 1:859-859
Rapamycin is an immunosuppressant and anticancer drug that extends lifespan in model organisms including mice, but side effects including metabolic disruption may limit its wide-scale use for diseases of aging. We have previously found that many side
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82f61cd428c91f2546df0191e9240cdc
https://doi.org/10.1093/geroni/igx004.3091
https://doi.org/10.1093/geroni/igx004.3091